The project will develop digital technologies to quantify vascular disease burden in patients with CNS diseases to support more accurate differential diagnosis of CNS diseases in the clinic, enabling the design and execution of better targeted clinical trials. MR imaging data and clinical data from patients with vascular disease will be evaluated with different algorithms that automatically quantify a subject’s vascular disease burden against current visual assessments. The developed vascular disease biomarkers will be incorporated into IXICO’s ASSESSA platform that uses technology developed by the BioMedIA group. The overall project aim is to providing clinicians with information that is clinically actionable and easy to interpret.
The BioMedIA group at Imperial College London is alongside IXICO and the University of Edinburgh in the project which is part-funded by Innovate UK (formerly the Technology Strategy Board), the UK’s innovation agency.